2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane has been researched along with Weight-Loss* in 2 studies
2 other study(ies) available for 2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane and Weight-Loss
| Article | Year |
|---|---|
Prediction of future weight change with dopamine transporter in patients with Parkinson's disease.
Fluctuating body weight is a commonly reported nonmotor feature in patients with Parkinson's disease (PD). We hypothesised that striatal dopamine transporter (DAT) density at the time of diagnosis might play an important role in weight regulation in patients with PD. DAT density was measured from Topics: Adult; Aged; Aged, 80 and over; Caudate Nucleus; Dopamine Plasma Membrane Transport Proteins; Female; Follow-Up Studies; Humans; Male; Middle Aged; Parkinson Disease; Prognosis; Putamen; Sex Factors; Tomography, Emission-Computed, Single-Photon; Tropanes; Weight Gain; Weight Loss | 2019 |
Weight loss is associated with rapid striatal dopaminergic degeneration in Parkinson's disease.
Weight loss in Parkinson's disease (PD) is associated with poorer clinical outcomes and rapid disease progression. However, it is unclear whether a longitudinal association between weight loss and striatal dopaminergic degeneration exists.. Using data from 171 PD patients in the Parkinson's Progression Markers Initiative (PPMI) cohort, we investigated longitudinal associations of change in body mass index (BMI) with striatal dopaminergic activity on. Our findings suggest a potential association between striatal dopaminergic activity with body weight or impairment in energy homeostasis. Body weight and its change may be a clinical biomarker reflecting striatal dopaminergic dysfunction in PD. Topics: Aged; Body Mass Index; Disease Progression; Dopamine Plasma Membrane Transport Proteins; Dopaminergic Neurons; Female; Humans; Longitudinal Studies; Male; Middle Aged; Neostriatum; Parkinson Disease; Tomography, Emission-Computed, Single-Photon; Tropanes; Weight Loss | 2018 |